EMAGIX is an early stage biomedical company that has developed an algorithm-driven approach for diagnosis of retinal and brain vascular injury.
There is an emerging consensus of the key role of leaky blood vessels in the development of a wide range of ophthalmic and neurologic disorders. With the growth in the number of people affected by diabetes, Emagix is focused on preventing visual loss.
The company’s technology will identify subtle changes in vascular functions and monitor the rate of progression and response to treatment.
1344 Summer Street
Halifax NS B3H 0A8